As the Managing Site Head of Quotient’s Chelsea Parkway and Garnet Valley Locations, Nutan Gangrade has overseen over 200 clinical manufacturing programs and manufacture of 5 commercial products in the 17 years that he has been with the organization.
1. Looking back to when you were first starting in your career, was your goal to be where you are now? Tell us about your background, what you studied and how it all has led you to your current role here at Quotient?
After getting my graduate degree in Pharmaceutics from the University of Georgia, I started as a formulation scientist at Chase Pharmaceutical Company in Newark, NJ. At Chase I was mainly involved in developing generic formulations. During my short tenure there, I learned about many of the manufacturing techniques and the basics of GMP. Then I moved to American Cyanamid Company where I got extensive training and learned about the whole process of drug development from discovery to launch. I had the opportunity to lead the product development group and be part of several teams including discovery chemistry/pharmacology, toxicology, IND CMC development, scale up and technology transfer to commercial manufacturing site. Later I worked at Wyeth Ayerst, Dupont Merck, and Bristol Myers Squibb in the CMC product development before joining QS Pharma in 2002, which was acquired by Quotient Sciences in 2017.
2. You mentioned that you started off at the bench as a formulator, how was the transition from the sponsor side to the CDMO side of the drug development business and why did you decide to make that leap? What have you enjoyed most about working in the CDMO environment? Do you ever find yourself tapping into your experience as a formulator when meeting with clients and discussing their projects?
My formulator-experience formed the foundation of my career. I learned a lot about development, quality and regulatory aspects of the industry. I decided to leave BMS and work for a start-up CDMO primarily to be able to help virtual and small companies that could not undertake development in-house. The goal was to provide the best chance of success for their molecules in clinical studies. It has been a very rewarding experience working on the CDMO side. My experience in big pharma plays a key role in my thinking when we interact with our customers. I want our team to be an extension of our customers’ team. Our teams have worked on several products, many of which are in the market now.
3. As a managing director of both of Quotient’s Philadelphia sites, what does your day-to-day look like? What do you enjoy most about your role and how do you see your role evolving over time as the business grows?
For all of us at Quotient, the day is always extremely busy but I look forwarding to coming to work every day. There are many sides of my work that are gratifying in many ways. Firstly, we work for a noble cause - we develop and manufacture drugs that help treat serious diseases. We are helping the patients by bringing the drugs to them as quickly as possible. Secondly, it is absolutely the most wonderful group of people that I have ever worked with. As a team, we have achieved many successes and grown the company 10 fold over the past 9 years. It is a great joy to see Quotient continue to grow and more colleagues joining us. We have hired and trained many fresh talents who are now in leading positions and I see myself helping to take Quotient to the next level as we undergo our next cycle of growth.
4. Prior to the Quotient acquisition in 2017, you were with QS Pharma for almost 12 years at the Chelsea Parkway facility. Tell us about the facility and programs that Chelsea Parkway is able to support? Since the Quotient acquisition, what additions and improvements have been made to the facility to better support our client’s needs?
Our Chelsea Parkway facility started in 2002 as a CDMO to provide early-stage development services to customers. Over the course of the next few years, the pharmaceutical industry changed its focus and we had to change our growth strategy. We decided to diversify our portfolio to include late-stage development and manufacturing. Over the next few years, the Chelsea Parkway site became more involved in process development and larger-scale manufacture of clinical supplies. By 2008, we had leased the entire building and expanded our analytical labs, GMP area and the warehouse. In 2012, we decided that we would manufacture products for the market. We expanded again and built a commercial manufacturing wing, more warehouse/dispensing areas and a large clean equipment GMP area. We built a team to support commercial manufacturing and in 2015, we had our first successful pre-approval inspection by the FDA. We launched our first commercial product in 2017 followed by four more. Today we have a very strong pipeline of early phase programs and many of these clients will stay with us through launch if their molecules are successful in clinical trials.
5. In addition to Chelsea Parkway, Quotient recently commissioned a brand-new facility just 2 miles down the road in Garnet Valley, PA. What was the need and overall goal in building this facility? What types of programs does this new facility support and what are the differences between the two sites?
As our late-stage portfolio is growing, we needed to expand to ensure we could support our customers’ early phase projects. Building the new Garnet Valley (GV) facility provided us with additional capacity but also enabled us to separate early-stage work from late-stage. The two require a different kind of facility and expertise. We decided to build the new facility from the ground up, which meant we were able to customize the specifications to our exact requirements. The new GV facility will house all early-phase development, Phase I-II CTM and support Translational Pharmaceutics programs in the US; where we can formulate and manufacture drug products and then integrate with clinical testing at our Miami clinical pharmacology facility. The Chelsea Parkway facility will now be dedicated to commercial manufacturing and some large-scale clinical/late-stage programs.
6. With all this expansion in facilities comes a need to continually increase headcount. How much has changed in terms of number of employees since you started up until now? What roles are we trying to fill?
Over the past 2 years, we have more than doubled our headcount and are continuing to hire people in almost every functional area. We are looking for dynamic people who are customer and team oriented. I am proud to say that the Quotient brand has helped the site attract high-caliber staff. Our goal is to make the company the best place to work at in our industry.
7. Quotient Sciences is growing in leaps and bounds, with the Philadelphia facilities representing 2 out of the 6 total Quotient facilities. How do the Philadelphia sites fit in to the mix? Do each of the sites offer different or the same/similar services? Do they ever work on projects together and transfer amongst one another? What do you think is one of the biggest successes at the Philadelphia locations?
The acquisition of Philadelphia site was an extremely significant strategic step in the growth plan for Quotient as it provided the capabilities and experience to continue to work with clients beyond Phase I/II and develop or transfer client products for further scale up. The Philadelphia facilities also provided Quotient with a footprint in the US where the highest number of pharma and biotech customers reside. Subsequently, with the Reading UK site also being added, Quotient now has a good mix of early and late development capabilities on both sides of the pond. Over last couple of years, we have successfully used our global footprint to help customers advance their programs into later stages of development. A recent example is with the company DRGT and this is described in our case study. DRGT has worked with all six of the Quotient sites over the past few years, on a program, which started out in Phase I and is now nearing commercial launch.
8. You mentioned that you consider the accomplishment of the US Translational Pharmaceutics studies this past year to be one of the Philadelphia sites biggest successes. Now that Quotient has a Phase I clinic in Miami, the Philadelphia facilities are able to conduct Translational Pharmaceutics programs in the US to mirror the hundreds of studies already conducted in the UK. This platform has helped accelerate our client’s timelines and drastically reduced development costs, which no other CDMO can offer. Do you think that this will greatly change the types of development programs that the Philadelphia sites support? What else do you think differentiates Quotient from other small molecule CDMO’s in the local area and the world?
Quotient’s Translational Pharmaceutics platform has been a main differentiator for our UK sites for years and our goal is to have that be the case for the US sites as well. We are already bringing in Translational Pharmaceutics programs into our Garnet Valley facility and continuously working with potential customers that will utilize our innovative platform. Not only does this save customers significant time and money, our customers can then quickly transition to later stage clinical supplies without losing time. This huge differentiator sets us apart from other small molecule CDMO’s in the local area and the world. There is no other company like ours in the world that can provide such scientifically sound, efficient and quality drug development that saves money and time. I hope that more customers will take advantage of our expertise and services.
9. When you started out, a lot of the initial work/projects you ran were early R&D for local businesses in the PA/NJ areas. This was a major part of the Philadelphia growth story. Can you talk more about those projects and how they directly contributed to the growth in Philadelphia?
The work in our early days of existence grounded us as a reliable and flexible service provider who could develop products and meet customers’ expectations of quality and speed. Some of the clinical formulations that we developed eventually got approval for the market.
10. Local pharmaceutical companies still represent a good portion of the clients that come through the Philadelphia facilities. How do local biotech/pharmaceutical companies benefit from the collaboration with a development and manufacturing company on their doorstep?
Whilst the Philadelphia sites support clients from all over the world, proximity plays a very significant role in our business. Many of our customers are located on the east coast and most of the time, our customers want to be at our site for observing manufacturing or development activities or for face-to-face meetings. It is very convenient for customers close by to make a short trip to oversee their project without losing too much time from their busy schedule.